July 2026 in “Clinical Case Reports” This single-patient case study reported promising results for severe, corticosteroid-resistant alopecia areata, with treatment using exosomes derived from mesenchymal stromal cells leading to almost complete hair regrowth in 12 weeks and favorable changes in inflammatory markers, suggesting potential for further investigation.
1 citations
,
February 2024 in “ACS applied bio materials” In a rat skin wound model, this study observed that a composite dressing using chitosan hydrogel and exosomes derived from adipose mesenchymal stem cells enhanced wound healing by promoting collagen deposition, angiogenesis, and regeneration of hair follicle structures.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” This narrative review highlights the potential of autologous adipose mesenchymal stem cell-derived exosomes (AMSCs-Exos) in anti-skin aging, noting their superior biocompatibility and manufacturing advantages while stressing the need for standardized production protocols to overcome existing application challenges.
April 2025 in “Journal of Investigative Dermatology” This study discovered that exosomes from adipose-derived mesenchymal stem cells can mitigate damage in dermal papilla cells by modulating the TGF-β1/SMAD2 signaling pathway through miRNAs miR-574-3p and miR-125a-5p, revealing potential therapeutic targets for androgenetic alopecia.
October 2025 in “Preprints.org” This research concludes that adipose mesenchymal stem cells are uniquely evolved to manage skin inflammation in newborns and their released molecules are the safest and most effective for skin therapeutics.
